GX-I7

Phase 1Small molecule

PPT Kalbe Genexine Biologics

GX-I7 is one of 63 small molecule programs targeting Glioblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlioblastomaActive, not recruiting

COVID-19Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 2

SARS-COV-2 VACCINE

Moderna

Preclinical

2 3

Selenium

SSWOG Cancer Research Network

Preclinical

1 4

Conventional

PPopulation Health Research Institute

Preclinical

1 5

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 7

GX-I7

PPT Kalbe Genexine Biologics

Phase 1

2 8

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 9

Moderna COVID-19 Vaccine

Moderna

Preclinical

4 10

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma3 trials

Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Completed·GGenexine, Inc.·Phase 1·NCT03619239·15 enrolled

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Withdrawn·GGenexine, Inc.·Phase 1/2·NCT04065087

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Unknown status·GGenexine, Inc.·Phase 2·NCT05191784·20 enrolled

Pembrolizumab2 trials

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Completed·GGenexine, Inc.·Phase 1/2·NCT03752723·84 enrolled

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Recruiting·SSL VAXiGEN·Phase 1·NCT06344715·78 enrolled

COVID-192 trials

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

Terminated·GGenexine, Inc.·Phase 1·NCT04730427·10 enrolled

A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19

Unknown status·PPT Kalbe Genexine Biologics·Phase 2·NCT04810637·210 enrolled

MPA1 trial

Individual Patient Compassionate Use of GX-I7

No longer available·GGenexine, Inc.··NCT04289155

Solid Tumors1 trial

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Completed·GGenexine, Inc.·Phase 1·NCT03733587·24 enrolled

3 more indications

Clinical Trial1 trial

Clinical Trial of GX-I7 in Healthy Volunteers

Completed·GGenexine, Inc.·Phase 1·NCT02860715·30 enrolled

Female1 trial

Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Completed·GGenexine, Inc.·Phase 1·NCT03144934·32 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Completed·GGenexine, Inc.·Phase 1·NCT03478995·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for GX-I7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GX-I7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GX-I7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PT Kalbe Genexine Biologics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPT Kalbe Genexine Biologics

GX-I7

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma3 trials

Pembrolizumab2 trials

COVID-192 trials

MPA1 trial

Solid Tumors1 trial

Clinical Trial1 trial

Female1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News